Johnson & Johnson Operating Expenses 2010-2024 | JNJ
Johnson & Johnson annual/quarterly operating expenses history and growth rate from 2010 to 2024. Operating expenses can be defined as the sum of all operating expenses for the given industry.
- Johnson & Johnson operating expenses for the quarter ending September 30, 2024 were $19.133B, a 18.59% increase year-over-year.
- Johnson & Johnson operating expenses for the twelve months ending September 30, 2024 were $70.070B, a 10.19% increase year-over-year.
- Johnson & Johnson annual operating expenses for 2023 were $70.097B, a 15.61% increase from 2022.
- Johnson & Johnson annual operating expenses for 2022 were $60.631B, a 1.79% increase from 2021.
- Johnson & Johnson annual operating expenses for 2021 were $59.562B, a 9.87% decline from 2020.
Johnson & Johnson Annual Operating Expenses (Millions of US $) |
2023 |
$70,097 |
2022 |
$60,631 |
2021 |
$59,562 |
2020 |
$66,087 |
2019 |
$64,731 |
2018 |
$63,582 |
2017 |
$58,777 |
2016 |
$52,087 |
2015 |
$50,878 |
2014 |
$53,768 |
2013 |
$55,841 |
2012 |
$53,449 |
2011 |
$52,669 |
2010 |
$44,640 |
2009 |
$46,142 |
Johnson & Johnson Quarterly Operating Expenses (Millions of US $) |
2024-09-30 |
$19,133 |
2024-06-30 |
$16,699 |
2024-03-31 |
$17,669 |
2023-12-31 |
$16,569 |
2023-09-30 |
$16,134 |
2023-06-30 |
$15,213 |
2023-03-31 |
$22,181 |
2022-12-31 |
$10,063 |
2022-09-30 |
$14,824 |
2022-06-30 |
$18,180 |
2022-03-31 |
$17,564 |
2021-12-31 |
$8,531 |
2021-09-30 |
$19,489 |
2021-06-30 |
$16,650 |
2021-03-31 |
$14,892 |
2020-12-31 |
$20,828 |
2020-09-30 |
$16,681 |
2020-06-30 |
$14,396 |
2020-03-31 |
$14,182 |
2019-12-31 |
$16,529 |
2019-09-30 |
$19,082 |
2019-06-30 |
$13,521 |
2019-03-31 |
$15,599 |
2018-12-31 |
$17,272 |
2018-09-30 |
$15,925 |
2018-06-30 |
$15,857 |
2018-03-31 |
$14,528 |
2017-12-31 |
$17,635 |
2017-09-30 |
$14,860 |
2017-06-30 |
$14,091 |
2017-03-31 |
$12,191 |
2016-12-31 |
$13,782 |
2016-09-30 |
$12,539 |
2016-06-30 |
$13,578 |
2016-03-31 |
$12,188 |
2015-12-31 |
$14,053 |
2015-09-30 |
$12,980 |
2015-06-30 |
$12,046 |
2015-03-31 |
$11,799 |
2014-12-31 |
$15,551 |
2014-09-30 |
$11,657 |
2014-06-30 |
$13,869 |
2014-03-31 |
$12,691 |
2013-12-31 |
$15,605 |
2013-09-30 |
$13,908 |
2013-06-30 |
$13,084 |
2013-03-31 |
$13,244 |
2012-12-31 |
$14,458 |
2012-09-30 |
$13,457 |
2012-06-30 |
$14,440 |
2012-03-31 |
$11,094 |
2011-12-31 |
$15,937 |
2011-09-30 |
$11,894 |
2011-06-30 |
$13,175 |
2011-03-31 |
$11,663 |
2010-12-31 |
$13,416 |
2010-09-30 |
$10,763 |
2010-06-30 |
$11,110 |
2010-03-31 |
$9,351 |
2009-12-31 |
$13,947 |
2009-09-30 |
$10,836 |
2009-06-30 |
$10,976 |
2009-03-31 |
$10,383 |
Sector |
Industry |
Market Cap |
Revenue |
Medical |
Large Cap Pharmaceutical |
$368.366B |
$85.159B |
Johnson & Johnson's biggest strength is its diversified business model. It operates through pharmaceuticals, medical devices and consumer products divisions. Its diversification helps it to withstand economic cycles more effectively. J&J has one of the largest research and development (R&D) budget among pharma companies. J&J's worldwide business is divided into three segments: Pharmaceutical, Medical Devices and Consumer. The company has several drugs covering a broad range of areas such as neuroscience, cardiovascular & metabolism, immunology, oncology, pulmonary hypertension and infectious diseases and vaccines. The Medical Devices Segment offers products in the orthopedics, surgery, interventional solutions and vision markets. The Consumer Segment segment includes a broad range of products covering the areas of baby care, beauty/skin health, oral care, wound care and womens' health care, as well as over-the-counter (OTC) pharmaceutical products.
|